
Investors Eye Class Action Against ADMA Biologics Following Stock Slide
Investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, face an August 10 deadline to seek lead plaintiff status in a federal class action lawsuit. The litigation targets alleged securities violations following reports of questionable revenue practices and undisclosed related-party transactions.
























